Impact of TechLive Remote Screening Technology on Imaging Capacity
TechLive, FDA-cleared, enables remote scanning of MRI, CT, PET/CT, and ultrasound procedures, significantly improving operational efficiency.
In a pilot at 64 New York locations, TechLive reduced MRI room closures by 42% in Q2 2025 compared to Q2 2024.
Implementation of TechLive has expanded center operating hours, allowing for more procedures without additional staffing, with a potential capacity increase of up to 40% in busy centers.
The technology has demonstrated the ability to staff exam rooms more effectively, reducing closures and increasing patient throughput, especially in high-demand markets.
RadNet aims to connect over 300 systems with TechLive by early 2026, which could substantially increase advanced imaging capacity and revenue.
Strategic Expansion and Development of Droplet Digital PCR (ddPCR) Portfolio
Completion of the development of the QX Continuum platform and successful acquisition of Stilla Technologies, adding new platforms and team members.
Launch of the rebranded QX700 Series ddPCR instruments synchronized with the Stilla acquisition, aimed at expanding the ddPCR portfolio.
Early positive customer feedback on the new ddPCR platforms, with plans to showcase innovations at the ddPCR World Conference in Seoul, Korea, in September.
Support for partners like Incyte and Genoscopy in bringing ddPCR technology to clinical markets, including FDA approval support and inclusion in NCCN guidelines.
Market expansion strategy to increase the number of ddPCR users, not just replacing existing platforms but broadening application scope.
RYTELO US Market Commercial Strategy and Demand Growth
RYTELO net revenues reached $49 million in Q2, up 24% from Q1, driven by increased demand from new patient starts.
Demand growth in Q2 was 17% quarter-over-quarter, with early signs of success from commercial strategies.
Approximately 1,000 sites of care have used RYTELO to date, with about 600+ patients estimated from reorders.
Market research indicates 30% of new patient starts are in first and second lines, with an expectation of increased use in earlier lines as physicians gain confidence.
Payer coverage has improved to 90% of covered lives under favorable policies, up from 85%.
The commercial team expanded by over 20%, with trained staff now deployed, expected to impact by year-end.
Efforts include increasing brand awareness, education, and KOL engagement to drive prescribing confidence and advocacy.
The company is focusing on educating physicians about RYTELO's differentiation and expanding outreach to community HCPs.
U.S. Launch Growth and Real-World Data for Amtagvi
Iovance has surpassed 100 patients treated in a single quarter for the first time with Amtagvi, indicating strong adoption.
Real-world data shows a nearly 49% response rate overall and approximately 61% in patients treated in earlier lines, reinforcing the therapy's durability.
The company plans to onboard large community practices in Q4, targeting earlier treatment settings and potentially higher response rates.
Demand is driven by increased field activities, new centers, and strategic distribution channels like specialty pharmacies, expanding access in community settings.
Management emphasizes the potential for peak U.S. sales of $1 billion or more, with international markets offering additional growth opportunities.
The focus on earlier treatment settings and community oncology networks aims to position Amtagvi as a preferred option for appropriate patients.
Rapid Adoption and Market Impact of IDEXX inVue Dx Platform
InVue Dx placements reached nearly 2,700 units globally by June 2025, exceeding initial expectations and leading to an increased placement forecast of 5,500 units for 2025.
Early customer feedback highlights the platform's workflow efficiency, rapid turnaround, and AI-powered diagnostic confidence.
InVue Dx is expected to support long-term recurring revenue growth, with upcoming launches like FNA for lumps and bumps.
Demand exceeds expectations, with high customer retention and strong demand for consumables, contributing to a 23% year-over-year increase in premium instrument placements.
The platform is reshaping point-of-care cytology testing, with a focus on high-quality, rapid results that support broader adoption in wellness and diagnostic workflows.
Progress Toward 100 Nanox.ARC System Installations and Market Expansion
Nanox is on track to meet its goal of 100 system installations by the end of 2025, with over 20 systems currently operational and scanning patients.
The company has expanded its pipeline significantly, with a focus on U.S. small- and medium-sized clinics and several European countries including Romania and Greece.
A notable installation is at Keiser University, integrating Nanox.ARC into radiology education, which aims to train future radiologists early in their careers.
Nanox is developing a mobile imaging solution that will bring high-quality diagnostics directly to clinics via a traveling medical imaging vehicle, expanding access and revenue opportunities.
Dafinchi